TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean Maximum Concentration (Cmax) of EE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Area Under the Concentration-time Curve (AUC) of EE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Maximum Concentration (Cmax) of DRSP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Area Under the Concentration-time Curve (AUC) of DRSP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Maximum Concentration (Cmax) of L-5-methyl-THF (Baseline Corrected)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cancer survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Absolute Change From Baseline in Left Ventricular Ejection Fraction (LVEF) (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Absolute Change From Baseline in Log-transformed NT-pro B-type Natriuretic Peptide (BNP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of Postoperative Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Presence and severity of PTSD symptoms: clinician-rated
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Presence and severity of PTSD symptoms: self-report
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum Tolerated Dose (MTD) of ricolinostat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Improvement in Shock Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Days Until Neutrophil Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of participants who experienced Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Tourniquet Inflation Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: presence of sinus rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: vascular cerebral attack
Endpoint domain: Mortality/survival
Primary endpoint: renal failure with a need of haemodialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Sperm DNA fragmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Adverse events (and serious adverse events) causally related to experimental treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Local, regional or systemic infections related with the implant
Endpoint domain: Adverse events/effects
Primary endpoint: Implant status (integrity, detachment and reabsorption)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of complications associated with sutures
Endpoint domain: Adverse events/effects
Primary endpoint: Long term cardiovascular outcome (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: control of mild-to-moderate bleeding during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: degree of paraspinal muscle degeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prevalence of potentially inappropriate medication (PIM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amputation level on each side
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume Output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Residual Cancer Burden-index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of deep vein thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline of the Blood Flow for the Total Renal Arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change From Baseline of the Portal Pressure Gradient (PPG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change From Baseline in Calorie Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concordance of initial treatment after FoCUS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: observed hospital mortality
Endpoint domain: Mortality/survival
Primary endpoint: difference in SOFA scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fMRI Signal Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Diurnal IOP Change From Baseline at Month 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Clinical resolution of treated warts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of wart-associated symptoms
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Timing relative to vaccination date for serious medically attended events
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of serious medically attended events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of serious medically attended events
Endpoint domain: Adverse events/effects
Primary endpoint: response and complete remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in mean 24-hour ABPM SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of KOOS5
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to first occurrence of ischemic stroke, transient ischemic attack, intracerebral hemorrhage, other non-traumatic intracranial hemorrhage, or myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Increase in HIV-1 RNA viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Modified Ashworth Spasticity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neuromuscular and connective tissue outcomes
Primary endpoint: Significant Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Disease Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of patients with 2 grade improvement in Hidradenitis Suppurativa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impressions Scales - Severity and Improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of adverse outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Coronary Artery Dimension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Weight gain during follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: pulmonary shunt percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: status of airway inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: alveolar and bronchial exhaled nitric oxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Efficacy in Improving Arm Function Abilities Measured by the Change From Baseline in Motricity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy in Improving Arm Function Abilities Measured by the Change From Baseline in Nine Hole Peg Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Who Completed the Hand Rehabilitation Program
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Energy and nutrient content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of overall success rate
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Intramyocardial haemorrhage/microvascular damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Development of campylobacteriosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Immunologic responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in the Hamilton Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Body Mass Index (BMI in kg/m^2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemoglobin A1c or HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insomnia Severity Index (ISI) total score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Number of Participants With Any Hypoxemia Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With Any Hypotension Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Global Tolerance for Flexible Bronchoscopy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction/cessation of alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Reactive Hyperemia Index (RHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Subjective Assessments
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Paraspinal muscle volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Knee pain (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Tumor Infiltrating Lymphocytes (TILs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent Change in Tumor Associated Macrophages (TAMs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of the Regimen as Measured by Incidence of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Abdominal wall closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Area under the concentration time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient acceptability of devices
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average Resting Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gut microbiota diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and severity of adverse events with rifampicin (single drug)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and severity of adverse events with rifampicin (combined therapy)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in AXL pathway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients With a Severe Asthma Exacerbation
Endpoint domain: Adverse events/effects
Primary endpoint: Mean difference in change in Framingham Risk Score (FRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference in major CV events
Endpoint domain: Mortality/survival
Primary endpoint: Rate of Anastomotic leak
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients With Complete Hematologic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants With Seroconversion to Vaccine Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pressure Wave Reflection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in quality of life (QoL) for Patients
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline in quality of life (QoL) for Family Caregivers
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of subjects who meet the criteria of cure
Endpoint domain: Mortality/survival
Primary endpoint: insulin-mediated glucose disposal rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of nocturnal hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Free thyroxine (FT4) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cmax,ss (maximum observed concentration at steady state)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmin,ss (minimum observed concentration at steady state)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax,ss (Time of Cmax at steady state)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration time curve over the dosing interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CL/F (apparent total clearance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCGIR (0-60 min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change Score for HbA1c <9 Percent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change Score for LDL <100 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change Score for Blood Pressure (b.p.) <130/80 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Bacterial Indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Oxidative Stress Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of major infections
Endpoint domain: Adverse events/effects
Primary endpoint: Success Rates of the Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgery failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in blood calcium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fold changes of ncRNA expression between eosinophils subtypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ncRNA levels in rEOS- and iEOS-derived exosomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatitis B recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Quality of Life after surgery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: time to cervical dilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: induction abortion interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for surgical evacuation
Endpoint domain: Adverse events/effects
Primary endpoint: Time to first re-hospitalization and/or death
Endpoint domain: Mortality/survival
Primary endpoint: BETD (Best Overall Response Rate)
Endpoint domain: Adverse events/effects
Primary endpoint: Pain While at Rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum tolerated dose (MTD) of Cerebraca Wafer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of individuals that completed the intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Patient acceptance of expanded carrier screening
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient literacy of expanded carrier screening
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Chronic GVHD-Activity Index (CGVHD-AI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Structured questionnaire responses
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PHIS Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Headache Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Force from femoral and tibial side
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival Without Bronchopulmonary Dysplasia
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients who discontinued treatment due to study drug-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Overall response success rate at the end of ABCD treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mitochondrial Function (mtDNA Levels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and nature of grade IV toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of microvascular obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: anxiolytic value of touch massage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Staff and resource availability
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Baseline data of demographic and clinical characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of renal malignancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in subjective symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in corneal staining and injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative dosimetric differences for the target volume and normal structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance-corrected near visual acuity (DCNVA) at 30 cm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance-corrected intermediate visual acuity (DCIVA) at 60 cm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MTD (Maximum Tolerated Dose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of treatment emergent grade 3 or higher toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Prealbumin (PA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total bilirubin (TB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Direct bilirubin (DB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood urea nitrogen (BUN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete recovery in PACU without residual curarization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of the treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Language Sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact of Event Scale-Revised
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Timeline Follow Back
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of babies needing positive pressure ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: change in Quantitative electroencephalography (QEEG) results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: change in P300 results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adherence to Inhaled combination therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With ≥1 Adverse Event (AE) Through Week 36
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With ≥1 Serious Adverse Event (SAE) Through Week 36
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With an AE Resulting in Death Through Week 36
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma pharmacokinetics of PF-04427429
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: error rates of prescriptions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in pedal pressure during gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in plantar tissue thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Treatment Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PSTD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline to Week 26 in UPDRS Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes